Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.21
(4.97%)
SEK 0.21
(4.97%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 653.5 Million SEK | -5.36% |
| 2022 | 690.51 Million SEK | 0.3% |
| 2021 | 688.42 Million SEK | 48.44% |
| 2020 | 463.76 Million SEK | 36.83% |
| 2019 | 338.94 Million SEK | 34.03% |
| 2018 | 252.88 Million SEK | 127.91% |
| 2017 | 110.96 Million SEK | -6.05% |
| 2016 | 118.11 Million SEK | 56.79% |
| 2015 | 75.33 Million SEK | 1026.25% |
| 2014 | 6.68 Million SEK | -27.26% |
| 2013 | 9.19 Million SEK | 1299.58% |
| 2012 | 657 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 839.66 Million SEK | 0.3% |
| 2024 Q2 | 837.18 Million SEK | -6.84% |
| 2024 Q1 | 898.65 Million SEK | 37.51% |
| 2023 Q4 | 653.5 Million SEK | -26.64% |
| 2023 Q1 | 650.92 Million SEK | -5.73% |
| 2023 FY | 653.5 Million SEK | -5.36% |
| 2023 Q3 | 890.81 Million SEK | -10.8% |
| 2023 Q2 | 998.71 Million SEK | 53.43% |
| 2022 FY | 690.51 Million SEK | 0.3% |
| 2022 Q3 | 582.45 Million SEK | -14.81% |
| 2022 Q2 | 683.69 Million SEK | 1.18% |
| 2022 Q1 | 675.72 Million SEK | -1.84% |
| 2022 Q4 | 690.51 Million SEK | 18.55% |
| 2021 Q1 | 473.75 Million SEK | 2.15% |
| 2021 FY | 688.42 Million SEK | 48.44% |
| 2021 Q4 | 688.42 Million SEK | -1.23% |
| 2021 Q3 | 696.99 Million SEK | 81.6% |
| 2021 Q2 | 383.8 Million SEK | -18.99% |
| 2020 Q1 | 311.35 Million SEK | -8.14% |
| 2020 Q4 | 463.76 Million SEK | 46.72% |
| 2020 Q3 | 316.08 Million SEK | -27.76% |
| 2020 FY | 463.76 Million SEK | 36.83% |
| 2020 Q2 | 437.52 Million SEK | 40.52% |
| 2019 Q2 | 455.18 Million SEK | 54.74% |
| 2019 Q1 | 294.16 Million SEK | 16.32% |
| 2019 FY | 338.94 Million SEK | 34.03% |
| 2019 Q4 | 338.94 Million SEK | -16.6% |
| 2019 Q3 | 406.41 Million SEK | -10.72% |
| 2018 Q1 | 130.13 Million SEK | 17.28% |
| 2018 FY | 252.88 Million SEK | 127.91% |
| 2018 Q4 | 252.88 Million SEK | -8.08% |
| 2018 Q3 | 275.12 Million SEK | 117.42% |
| 2018 Q2 | 126.54 Million SEK | -2.76% |
| 2017 Q1 | 111.09 Million SEK | -5.94% |
| 2017 Q2 | 119.46 Million SEK | 7.53% |
| 2017 Q3 | 117.57 Million SEK | -1.58% |
| 2017 Q4 | 110.96 Million SEK | -5.63% |
| 2017 FY | 110.96 Million SEK | -6.05% |
| 2016 Q2 | 140.48 Million SEK | -6.84% |
| 2016 Q3 | 131.11 Million SEK | -6.67% |
| 2016 Q4 | 118.11 Million SEK | -9.92% |
| 2016 FY | 118.11 Million SEK | 56.79% |
| 2016 Q1 | 150.79 Million SEK | 100.18% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q3 | 76.48 Million SEK | 0.0% |
| 2015 Q4 | 75.33 Million SEK | -1.51% |
| 2015 FY | 75.33 Million SEK | 1026.25% |
| 2014 FY | 6.68 Million SEK | -27.26% |
| 2014 Q4 | 6.68 Million SEK | 0.0% |
| 2013 FY | 9.19 Million SEK | 1299.58% |
| 2012 FY | 657 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | -430.492% |
| Amniotics AB (publ) | 26.08 Million SEK | -2405.206% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -10653.793% |
| BioArctic AB (publ) | 1.18 Billion SEK | 44.902% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 65.615% |
| Genovis AB (publ.) | 288.85 Million SEK | -126.239% |
| LIDDS AB (publ) | 17.65 Million SEK | -3601.546% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -134.447% |
| OncoZenge AB (publ) | 20.34 Million SEK | -3112.92% |
| Saniona AB (publ) | 64.14 Million SEK | -918.83% |
| Simris Alg AB (publ) | 174.55 Million SEK | -274.392% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -31.69% |
| AcouSort AB (publ) | 34.51 Million SEK | -1793.513% |
| Active Biotech AB (publ) | 44 Million SEK | -1385.245% |
| Camurus AB (publ) | 1.9 Billion SEK | 65.746% |
| Cantargia AB (publ) | 223.71 Million SEK | -192.12% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -4295.104% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -666.785% |
| Mendus AB (publ) | 755.95 Million SEK | 13.552% |
| Kancera AB (publ) | 65.64 Million SEK | -895.549% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 48.068% |
| Lipum AB (publ) | 12.11 Million SEK | -5296.433% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -1844.849% |
| NextCell Pharma AB | 81.28 Million SEK | -703.941% |
| Xintela AB (publ) | 18.39 Million SEK | -3452.639% |
| Ziccum AB (publ) | 14.97 Million SEK | -4264.868% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -2065.868% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -3160.855% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -364.809% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 14.603% |
| CombiGene AB (publ) | 120.61 Million SEK | -441.827% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -201.103% |
| Intervacc AB (publ) | 259.61 Million SEK | -151.726% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -451.716% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -947.675% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -1457.492% |
| Corline Biomedical AB | 100.1 Million SEK | -552.823% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -268.961% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -951.467% |
| Aptahem AB (publ) | 63.02 Million SEK | -936.904% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -86.008% |
| Fluicell AB (publ) | 9.34 Million SEK | -6896.874% |
| Biovica International AB (publ) | 131.4 Million SEK | -397.312% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -1133.383% |
| Abliva AB (publ) | 87.49 Million SEK | -646.875% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 14.035% |
| 2cureX AB (publ) | 16.62 Million SEK | -3830.875% |
| I-Tech AB | 152.44 Million SEK | -328.69% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 35.807% |
| Cyxone AB (publ) | 43.65 Million SEK | -1396.983% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -730.463% |
| Biosergen AB | 7.2 Million SEK | -8975.24% |
| Nanologica AB (publ) | 77.42 Million SEK | -744.009% |
| SynAct Pharma AB | 228.01 Million SEK | -186.602% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -2341.834% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 53.327% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -2911.159% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -174.148% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -7629.249% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -650.537% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -2192.367% |